{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:32:28Z","timestamp":1791772348949,"version":"4.3.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 108-2320-B-006-025-"],"award-info":[{"award-number":["MOST 108-2320-B-006-025-"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pancreatic ductal adenocarcinoma (PDAC) and cancer-associated cachexia (CAC) are multifactorial and characterized by dysregulated inflammatory networks. Whether the proinflammatory cytokine IL-20 is involved in the complex networks of PDAC and CAC remains unclear. Here, we report that elevated IL-20 levels in tumor tissue correlate with poor overall survival in 72 patients with\u00a0PDAC. In vivo, we establish a transgenic mouse model (KPC) and an orthotopic PDAC model and examine the therapeutic efficacy of an anti-IL-20 monoclonal antibody (7E). Targeting IL-20 not only prolongs survival and attenuates PD-L1 expression in both murine models but also inhibits tumor growth and mitigates M2-like polarization in the orthotopic PDAC model. Combination treatment with 7E and an anti-PD-1 antibody shows better efficacy in inhibiting tumor growth than either treatment alone in the orthotopic PDAC model. Finally, 7E mitigates cachexic symptoms in CAC models. Together, we conclude IL-20 is a critical mediator in PDAC progression.<\/jats:p>","DOI":"10.1038\/s41467-020-18244-8","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T10:03:01Z","timestamp":1600077781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["IL-20 antagonist suppresses PD-L1 expression and prolongs survival in pancreatic cancer models"],"prefix":"10.1038","volume":"11","author":[{"given":"Shao-Wei","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Chin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2738-2638","authenticated-orcid":false,"given":"Yu-Hsiang","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9665-5236","authenticated-orcid":false,"given":"Kung-Chao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7010-6220","authenticated-orcid":false,"given":"Li-Wha","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9325-8734","authenticated-orcid":false,"given":"Wei-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Shi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"key":"18244_CR1","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccr.2011.05.011","volume":"19","author":"C Guerra","year":"2011","unstructured":"Guerra, C. et al. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 19, 728\u2013739 (2011).","journal-title":"Cancer Cell"},{"key":"18244_CR2","first-page":"14.39.11","volume":"73","author":"JW Lee","year":"2016","unstructured":"Lee, J. W., Komar, C. A., Bengsch, F., Graham, K. & Beatty, G. L. Genetically engineered mouse models of pancreatic cancer: the KPC model (LSL-Kras(G12D\/+);LSL-Trp53(R172H\/+);Pdx-1-Cre), its variants, and their application in immuno-oncology drug discovery. Curr. Protoc. Pharmacol. 73, 14.39.11\u201314.39.20 (2016).","journal-title":"Curr. Protoc. Pharmacol."},{"key":"18244_CR3","doi-asserted-by":"crossref","first-page":"e0221169","DOI":"10.1371\/journal.pone.0221169","volume":"14","author":"D Kruger","year":"2019","unstructured":"Kruger, D., Yako, Y. Y., Devar, J., Lahoud, N. & Smith, M. Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: enhancing diagnostic accuracy. PLoS ONE 14, e0221169 (2019).","journal-title":"PLoS ONE"},{"key":"18244_CR4","doi-asserted-by":"crossref","first-page":"588.e10","DOI":"10.1016\/j.ccell.2019.02.009","volume":"35","author":"L Cassetta","year":"2019","unstructured":"Cassetta, L. et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell 35, 588.e10\u2013602.e10 (2019).","journal-title":"Cancer Cell"},{"key":"18244_CR5","doi-asserted-by":"crossref","first-page":"9119","DOI":"10.1007\/s13277-015-4127-2","volume":"36","author":"H Hu","year":"2015","unstructured":"Hu, H., Jiao, F., Han, T. & Wang, L. W. Functional significance of macrophages in pancreatic cancer biology. Tumour Biol. 36, 9119\u20139126 (2015).","journal-title":"Tumour Biol."},{"key":"18244_CR6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fcell.2018.00038","volume":"6","author":"L Cassetta","year":"2018","unstructured":"Cassetta, L. & Kitamura, T. Targeting tumor-associated macrophages as a potential strategy to enhance the response to immune checkpoint inhibitors. Front. Cell Dev. Biol. 6, 38 (2018).","journal-title":"Front. Cell Dev. Biol."},{"key":"18244_CR7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","volume":"67","author":"TA Mace","year":"2018","unstructured":"Mace, T. A. et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut 67, 320\u2013332 (2018).","journal-title":"Gut"},{"key":"18244_CR8","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2015-02-626754","volume":"126","author":"F McClanahan","year":"2015","unstructured":"McClanahan, F. et al. Mechanisms of PD-L1\/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Emicro-TCL1 CLL mouse model. Blood 126, 212\u2013221 (2015).","journal-title":"Blood"},{"key":"18244_CR9","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","volume":"13","author":"T Nomi","year":"2007","unstructured":"Nomi, T. et al. Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 13, 2151\u20132157 (2007).","journal-title":"Clin. Cancer Res."},{"key":"18244_CR10","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","volume":"5","author":"EM O\u2019Reilly","year":"2019","unstructured":"O\u2019Reilly, E. M. et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 5, 1431\u20131438 (2019).","journal-title":"JAMA Oncol."},{"key":"18244_CR11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC Ozdemir","year":"2014","unstructured":"Ozdemir, B. C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719\u2013734 (2014).","journal-title":"Cancer Cell"},{"key":"18244_CR12","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.tranon.2017.04.009","volume":"10","author":"L Bolm","year":"2017","unstructured":"Bolm, L. et al. The role of fibroblasts in pancreatic cancer: extracellular matrix versus paracrine factors. Transl. Oncol. 10, 578\u2013588 (2017).","journal-title":"Transl. Oncol."},{"key":"18244_CR13","volume":"9","author":"L Wei","year":"2018","unstructured":"Wei, L. et al. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1\/SATB-1 pathway in pancreatic cancer. Cell Death Dis. 9, 1065 (2018).","journal-title":"Cell Death Dis."},{"key":"18244_CR14","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0149-2918(05)80001-3","volume":"69","author":"WD Dewys","year":"1980","unstructured":"Dewys, W. D. et al. Prognostic effect of weight loss prior tochemotherapy in cancer patients. Am. J. Med. 69, 491\u2013497 (1980).","journal-title":"Am. J. Med."},{"key":"18244_CR15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1079\/PNS19920036","volume":"51","author":"KC Fearon","year":"1992","unstructured":"Fearon, K. C. The Sir David Cuthbertson Medal Lecture 1991. The mechanisms and treatment of weight loss in cancer. Proc. Nutr. Soc. 51, 251\u2013265 (1992).","journal-title":"Proc. Nutr. Soc."},{"key":"18244_CR16","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-9-255","volume":"9","author":"J Bachmann","year":"2009","unstructured":"Bachmann, J. et al. Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function. BMC Cancer 9, 255 (2009).","journal-title":"BMC Cancer"},{"key":"18244_CR17","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/gut.2004.047563","volume":"54","author":"JN Gordon","year":"2005","unstructured":"Gordon, J. N. et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54, 540\u2013545 (2005).","journal-title":"Gut"},{"key":"18244_CR18","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1158\/0008-5472.CAN-11-3536","volume":"72","author":"M Tsoli","year":"2012","unstructured":"Tsoli, M. et al. Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice. Cancer Res. 72, 4372\u20134382 (2012).","journal-title":"Cancer Res."},{"key":"18244_CR19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1126\/science.1198973","volume":"333","author":"SK Das","year":"2011","unstructured":"Das, S. K. et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 333, 233\u2013238 (2011).","journal-title":"Science"},{"key":"18244_CR20","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/0026-0495(81)90020-2","volume":"30","author":"P Arner","year":"1981","unstructured":"Arner, P., Bolinder, J., Engfeldt, P. & Ostman, J. The antilipolytic effect of insulin in human adipose tissue in obesity, diabetes mellitus, hyperinsulinemia, and starvation. Metabolism 30, 753\u2013760 (1981).","journal-title":"Metabolism"},{"key":"18244_CR21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cmet.2014.06.011","volume":"20","author":"M Petruzzelli","year":"2014","unstructured":"Petruzzelli, M. et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20, 433\u2013447 (2014).","journal-title":"Cell Metab."},{"key":"18244_CR22","first-page":"5488","volume":"60","author":"C Cahlin","year":"2000","unstructured":"Cahlin, C. et al. Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res. 60, 5488\u20135493 (2000).","journal-title":"Cancer Res."},{"key":"18244_CR23","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1146\/annurev.immunol.22.012703.104622","volume":"22","author":"S Pestka","year":"2004","unstructured":"Pestka, S. et al. Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol. 22, 929\u2013979 (2004).","journal-title":"Annu. Rev. Immunol."},{"key":"18244_CR24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0092-8674(01)00187-8","volume":"104","author":"H Blumberg","year":"2001","unstructured":"Blumberg, H. et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 104, 9\u201319 (2001).","journal-title":"Cell"},{"key":"18244_CR25","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.4049\/jimmunol.167.7.3545","volume":"167","author":"L Dumoutier","year":"2001","unstructured":"Dumoutier, L., Leemans, C., Lejeune, D., Kotenko, S. V. & Renauld, J. C. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J. Immunol. 167, 3545\u20133549 (2001).","journal-title":"J. Immunol."},{"key":"18244_CR26","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/cei.12973","volume":"189","author":"TW Kragstrup","year":"2017","unstructured":"Kragstrup, T. W. et al. Increased interleukin (IL)-20 and IL-24 target osteoblasts and synovial monocytes in spondyloarthritis. Clin. Exp. Immunol. 189, 342\u2013351 (2017).","journal-title":"Clin. Exp. Immunol."},{"key":"18244_CR27","volume":"7","author":"YS Chiu","year":"2017","unstructured":"Chiu, Y. S. et al. Anti-IL-20 monoclonal antibody inhibited tumor growth in hepatocellular carcinoma. Sci. Rep. 7, 17609 (2017).","journal-title":"Sci. Rep."},{"key":"18244_CR28","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.4049\/jimmunol.1102843","volume":"188","author":"YH Hsu","year":"2012","unstructured":"Hsu, Y. H. et al. Anti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murine models. J. Immunol. 188, 1981\u20131991 (2012).","journal-title":"J. Immunol."},{"key":"18244_CR29","doi-asserted-by":"crossref","first-page":"e0139871","DOI":"10.1371\/journal.pone.0139871","volume":"10","author":"YH Hsu","year":"2015","unstructured":"Hsu, Y. H. et al. Anti-IL-20 monoclonal antibody suppresses prostate cancer growth and bone osteolysis in murine models. PLoS ONE 10, e0139871 (2015).","journal-title":"PLoS ONE"},{"key":"18244_CR30","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1158\/1541-7786.MCR-12-0276","volume":"10","author":"YH Hsu","year":"2012","unstructured":"Hsu, Y. H., Wei, C. C., Shieh, D. B., Chan, C. H. & Chang, M. S. Anti-IL-20 monoclonal antibody alleviates inflammation in oral cancer and suppresses tumor growth. Mol. Cancer Res. 10, 1430\u20131439 (2012).","journal-title":"Mol. Cancer Res."},{"key":"18244_CR31","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.4049\/jimmunol.178.4.2229","volume":"178","author":"SM Sa","year":"2007","unstructured":"Sa, S. M. et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J. Immunol. 178, 2229\u20132240 (2007).","journal-title":"J. Immunol."},{"key":"18244_CR32","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1002\/art.22039","volume":"54","author":"YH Hsu","year":"2006","unstructured":"Hsu, Y. H. et al. Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum. 54, 2722\u20132733 (2006).","journal-title":"Arthritis Rheum."},{"key":"18244_CR33","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1161\/01.ATV.0000232502.88144.6f","volume":"26","author":"WY Chen","year":"2006","unstructured":"Chen, W. Y., Cheng, B. C., Jiang, M. J., Hsieh, M. Y. & Chang, M. S. IL-20 is expressed in atherosclerosis plaques and promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 26, 2090\u20132095 (2006).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"18244_CR34","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/gene.2008.28","volume":"9","author":"HH Li","year":"2008","unstructured":"Li, H. H. et al. Interleukin-20 induced cell death in renal epithelial cells and was associated with acute renal failure. Genes Immun. 9, 395\u2013404 (2008).","journal-title":"Genes Immun."},{"key":"18244_CR35","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.4049\/jimmunol.0803653","volume":"182","author":"WY Chen","year":"2009","unstructured":"Chen, W. Y. & Chang, M. S. IL-20 is regulated by hypoxia-inducible factor and up-regulated after experimental ischemic stroke. J. Immunol. 182, 5003\u20135012 (2009).","journal-title":"J. Immunol."},{"key":"18244_CR36","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","volume":"7","author":"SR Hingorani","year":"2005","unstructured":"Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469\u2013483 (2005).","journal-title":"Cancer Cell"},{"key":"18244_CR37","volume":"32","author":"Y Wang","year":"2015","unstructured":"Wang, Y. et al. PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma. Med. Oncol. 32, 212 (2015).","journal-title":"Med. Oncol."},{"key":"18244_CR38","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-015-0421-2","volume":"14","author":"A Alsuliman","year":"2015","unstructured":"Alsuliman, A. et al. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol. Cancer 14, 149 (2015).","journal-title":"Mol. Cancer"},{"key":"18244_CR39","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/hep.27189","volume":"60","author":"YS Chiu","year":"2014","unstructured":"Chiu, Y. S., Wei, C. C., Lin, Y. J., Hsu, Y. H. & Chang, M. S. IL-20 and IL-20R1 antibodies protect against liver fibrosis. Hepatology 60, 1003\u20131014 (2014).","journal-title":"Hepatology"},{"key":"18244_CR40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/713774061","volume":"9","author":"MJ Eppihimer","year":"2002","unstructured":"Eppihimer, M. J. et al. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 9, 133\u2013145 (2002).","journal-title":"Microcirculation"},{"key":"18244_CR41","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1084\/jem.20161707","volume":"214","author":"D Daley","year":"2017","unstructured":"Daley, D. et al. NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma. J. Exp. Med. 214, 1711\u20131724 (2017).","journal-title":"J. Exp. Med."},{"key":"18244_CR42","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"18244_CR43","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ccr.2005.10.004","volume":"8","author":"S Acharyya","year":"2005","unstructured":"Acharyya, S. et al. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 8, 421\u2013432 (2005).","journal-title":"Cancer Cell"},{"key":"18244_CR44","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/0026-0495(87)90132-6","volume":"36","author":"A Legaspi","year":"1987","unstructured":"Legaspi, A., Jeevanandam, M., Starnes, H. F. Jr. & Brennan, M. F. Whole body lipid and energy metabolism in the cancer patient. Metabolism 36, 958\u2013963 (1987).","journal-title":"Metabolism"},{"key":"18244_CR45","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature13528","volume":"513","author":"S Kir","year":"2014","unstructured":"Kir, S. et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature 513, 100\u2013104 (2014).","journal-title":"Nature"},{"key":"18244_CR46","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1158\/0008-5472.CAN-06-4585","volume":"67","author":"T Agustsson","year":"2007","unstructured":"Agustsson, T. et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res. 67, 5531\u20135537 (2007).","journal-title":"Cancer Res."},{"key":"18244_CR47","doi-asserted-by":"crossref","first-page":"40477","DOI":"10.1074\/jbc.M111.257923","volume":"286","author":"X Yang","year":"2011","unstructured":"Yang, X., Zhang, X., Heckmann, B. L., Lu, X. & Liu, J. Relative contribution of adipose triglyceride lipase and hormone-sensitive lipase to tumor necrosis factor-\u03b1 (TNF-\u03b1)-induced lipolysis in adipocytes. J. Biol. Chem. 286, 40477\u201340485 (2011).","journal-title":"J. Biol. Chem."},{"key":"18244_CR48","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1152\/physrev.00016.2008","volume":"89","author":"MJ Tisdale","year":"2009","unstructured":"Tisdale, M. J. Mechanisms of cancer cachexia. Physiol. Rev. 89, 381\u2013410 (2009).","journal-title":"Physiol. Rev."},{"key":"18244_CR49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molimm.2017.12.003","volume":"110","author":"KB Long","year":"2019","unstructured":"Long, K. B., Collier, A. I. & Beatty, G. L. Macrophages: key orchestrators of a tumor microenvironment defined by therapeutic resistance. Mol. Immunol. 110, 3\u201312 (2019).","journal-title":"Mol. Immunol."},{"key":"18244_CR50","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.gastro.2015.04.010","volume":"149","author":"GL Beatty","year":"2015","unstructured":"Beatty, G. L. et al. Exclusion of T cells from pancreatic carcinomas in mice is regulated by Ly6C(low) F4\/80(+) extratumoral macrophages. Gastroenterology 149, 201\u2013210 (2015).","journal-title":"Gastroenterology"},{"key":"18244_CR51","first-page":"550","volume":"61","author":"M L\u00f6hr","year":"2001","unstructured":"L\u00f6hr, M. et al. Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res. 61, 550\u2013555 (2001).","journal-title":"Cancer Res."},{"key":"18244_CR52","first-page":"667","volume":"18","author":"N Anggorowati","year":"2017","unstructured":"Anggorowati, N. et al. Histochemical and immunohistochemical study of \u03b1-SMA, collagen, and PCNA in epithelial ovarian neoplasm. Asian Pac. J. Cancer Prev. 18, 667\u2013671 (2017).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"18244_CR53","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1593\/tlo.11133","volume":"4","author":"H Yao","year":"2011","unstructured":"Yao, H. et al. Role of \u03b1(5)\u03b2(1) integrin up-regulation in radiation-induced invasion by human pancreatic cancer cells. Transl. Oncol. 4, 282\u2013292 (2011).","journal-title":"Transl. Oncol."},{"key":"18244_CR54","volume":"6","author":"AJ Rice","year":"2017","unstructured":"Rice, A. J. et al. Matrix stiffness induces epithelial-mesenchymal transition and promotes chemoresistance in pancreatic cancer cells. Oncogenesis 6, e352 (2017).","journal-title":"Oncogenesis"},{"key":"18244_CR55","volume":"9","author":"Y Liang","year":"2018","unstructured":"Liang, Y. et al. Targeting IFN\u03b1 to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance. Nat. Commun. 9, 4586 (2018).","journal-title":"Nat. Commun."},{"key":"18244_CR56","doi-asserted-by":"crossref","first-page":"TPS4148","DOI":"10.1200\/jco.2015.33.15_suppl.tps4148","volume":"33","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). J. Clin. Oncol. 33, TPS4148 (2015).","journal-title":"J. Clin. Oncol."},{"key":"18244_CR57","doi-asserted-by":"crossref","first-page":"TPS475","DOI":"10.1200\/jco.2016.34.4_suppl.tps475","volume":"34","author":"I Firdaus","year":"2016","unstructured":"Firdaus, I. et al. nab-paclitaxel (nab-P) + nivolumab (Nivo) \u00b1 gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC). J. Clin. Oncol. 34, TPS475 (2016).","journal-title":"J. Clin. Oncol."},{"key":"18244_CR58","doi-asserted-by":"crossref","first-page":"TPS465","DOI":"10.1200\/jco.2016.34.4_suppl.tps465","volume":"34","author":"ZA Wainberg","year":"2016","unstructured":"Wainberg, Z. A. et al. Phase 1\/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib\/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors. J. Clin. Oncol. 34, TPS465 (2016).","journal-title":"J. Clin. Oncol."},{"key":"18244_CR59","first-page":"2019","volume":"2080","author":"S Das","year":"2020","unstructured":"Das, S., Shapiro, B., Vucic, E. A., Vogt, S. & Bar-Sagi, D. Tumor cell-derived IL-1\u03b2 promotes desmoplasia and immune suppression in pancreatic cancer. Cancer Res. 2080, 2019 (2020).","journal-title":"Cancer Res."},{"key":"18244_CR60","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/jcsm.12377","volume":"10","author":"X Zhu","year":"2019","unstructured":"Zhu, X. et al. MyD88 signalling is critical in the development of pancreatic cancer cachexia. J. Cachexia Sarcopenia Muscle 10, 378\u2013390 (2019).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"18244_CR61","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ijc.20270","volume":"111","author":"MH Zaki","year":"2004","unstructured":"Zaki, M. H., Nemeth, J. A. & Trikha, M. CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int. J. Cancer 111, 592\u2013595 (2004).","journal-title":"Int. J. Cancer"},{"key":"18244_CR62","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1038\/s41598-017-02347-2","volume":"7","author":"G Zhang","year":"2017","unstructured":"Zhang, G. et al. Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways. Sci. Rep. 7, 2273\u20132273 (2017).","journal-title":"Sci. Rep."},{"key":"18244_CR63","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.gene.6364291","volume":"7","author":"MY Hsieh","year":"2006","unstructured":"Hsieh, M. Y. et al. Interleukin-20 promotes angiogenesis in a direct and indirect manner. Genes Immun. 7, 234\u2013242 (2006).","journal-title":"Genes Immun."},{"key":"18244_CR64","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.clim.2005.06.012","volume":"117","author":"CC Wei","year":"2005","unstructured":"Wei, C. C. et al. Detection of IL-20 and its receptors on psoriatic skin. Clin. Immunol. 117, 65\u201372 (2005).","journal-title":"Clin. Immunol."},{"key":"18244_CR65","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1084\/jem.20102234","volume":"208","author":"YH Hsu","year":"2011","unstructured":"Hsu, Y. H. et al. Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. J. Exp. Med. 208, 1849\u20131861 (2011).","journal-title":"J. Exp. Med."},{"key":"18244_CR66","doi-asserted-by":"crossref","unstructured":"Ying, W., Cheruku, P. S., Bazer, F. W., Safe, S. H. & Zhou, B. Investigation of macrophage polarization using bone marrow derived macrophages. J. Vis. Exp.\u00a076, e50323 (2013).","DOI":"10.3791\/50323"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18244-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18244-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18244-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T01:36:38Z","timestamp":1670290598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18244-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["18244"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-18244-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,14]]},"assertion":[{"value":"20 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4611"}}